Navigation Links
Thoratec Presentation at UBS Conference to be Webcast
Date:9/14/2009

PLEASANTON, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that will be participating in the UBS Global Life Sciences Conference on Tuesday, September 22.

David V. Smith, executive vice president and chief financial officer, will provide an update on the company beginning at 11:30 a.m., Eastern Daylight Time (8:30 a.m., Pacific Daylight Time).

The presentation will be available through the conference website at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=57_02G520B, or on the company's website at http://www.thoratec.com.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's websites at http://www.thoratec.com or http://www.itcmed.com.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction
2. Thoratec Schedules Second Quarter Conference Call, Webcast
3. Thoratec Announces Appointment of Paul LaViolette to Board of Directors
4. Thoratec Presentation at JMP Securities Conference to be Webcast
5. Thoratec Schedules First Quarter Conference Call, Webcast
6. Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission
7. Thoratec Presentation at Raymond James Conference to Be Webcast
8. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
9. Thoratec Reports 34 Percent Increase in 2008 Revenues
10. Thoratec Schedules Fiscal 2008 Year-End Conference Call, Webcast
11. Thoratec Presentation at Piper Jaffary Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® ... The program, developed in association with efforts by the American College of Surgeons, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Oily skin is a common and unwelcomed ... Advanced Dermatology has a lot to offer to the discussion of dealing with excess ... is that there are many home remedies that can help remove the oily shine while ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... Office (JPO) for the composition of matter of ... the treatment or prevention of fibrotic disorders, including ... retinopathy (Japanese Patent #: 6060071).  This patent includes ...
Breaking Medicine Technology: